Loteprednol etabonate , ≥98%(HPLC) , 82034-46-6
Synonym(s):
(11b,17a)-17-[(Ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-Androsta-1,4-diene-17-carboxylic acid chloromethyl ester;CDDD 5604;HGP 1;P 5604
CAS NO.：82034-46-6
Empirical Formula: C24H31ClO7
Molecular Weight: 466.95
MDL number: MFCD00870765
EINECS: 200-010-0
| Pack Size | Price | Stock | Quantity |
| 10MG | RMB23.20 | In Stock |
|
| 50MG | RMB79.20 | In Stock |
|
| 250MG | RMB273.60 | In Stock |
|
| 1g | RMB660.00 | In Stock |
|
| 5g | RMB2319.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 220.5-223.5 |
| Boiling point: | 600.1±55.0 °C(Predicted) |
| Density | 1.31±0.1 g/cm3(Predicted) |
| storage temp. | -20°C |
| solubility | DMSO: soluble5mg/mL, clear (warmed) |
| form | powder |
| pka | 14.06±0.70(Predicted) |
| color | white to beige |
| Water Solubility | <1mg/L(23 ºC) |
| Stability: | Hygroscopic |
| InChIKey | DMKSVUSAATWOCU-ICASLIHPSA-N |
Description and Uses
Loteprednol etabonate was introduced in the US as Lotemax (opththalmic suspension at 0.5%) for the treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the ocular globe, and as Alrex (opththalmic suspension at 0.2%) for the symptomatic treatment of seasonal allergic conjunctivitis. Loteprednol etabonate is a novel soft corticosteroid with a superior efficacy and an improved safety profile compared to prior ophthalmic steroids due to its metabolic lability and a fast enzymatic transformation to inactive metabolite. A combination of Lotemax with the antibiotic Tobramycin is currently under development.
An ophthalmic corticosteroid. Used as an anti-inflammatory.
Safety
| Symbol(GHS) |  GHS08 |
| Signal word | Warning |
| Hazard statements | H361-H413 |
| Precautionary statements | P501-P273-P202-P201-P280-P308+P313-P405 |
| WGK Germany | 3 |
| HS Code | 2937.22.0000 |
